Compare Nvidia Corp (NVDA) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nvidia Corp vs BIO-TECHNE Corp — how do they compare? Nvidia Corp trades at $217.18 (market cap $5.27T), while BIO-TECHNE Corp trades at $72.06 (market cap $11.24B). The key difference: Nvidia Corp is far larger — about 468.9× BIO-TECHNE Corp's market cap, and Nvidia Corp pays the higher dividend (0.46%). Which is the better fit depends on your goals.
| NVDA | TECH | |
|---|---|---|
Market Cap | $5.27T | $11.24B |
Sector | Technology | Health |
52-Week High | $235.75 | $72.29 |
52-Week Low | $165.17 | $43.31 |
Enterprise Value | $5.20T | $11.32B |
Dividend Yield | 0.46% | 0.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NVIDIA (NVDA) trades at $217.16, down 3.04% on the day, amid a broader tech sell-off. The stock exhibits strong fundamentals with a 55.84% net income margin and has beaten earnings estimates for three consecutive quarters. Technical indicators show a bullish trend with support near $215, while analyst sentiment remains overwhelmingly positive with a consensus price target of $325.86. Recent news highlights AI-driven growth prospects but also cautions about valuation and market rotation.
The outlook for NVDA is bullish based on accelerating AI demand and robust financials, though risks include high valuation multiples and increased competition. Investment opportunity lies in sustained earnings growth and market leadership, but investors should be wary of volatility and geopolitical factors affecting tech stocks.
Bio-Techne (TECH) trades at $72.29, up 0.54% today, with a bullish technical signal from moving averages and a consensus analyst price target of $71.67. Recent earnings showed mixed results, with a Q4 2025 beat but a Q1 2026 miss. The company maintains strong gross margins at 64.96% but faces declining net income margins, down to 6.01% in 2025. Positive cash flow trends and a pending acquisition by Merck highlight ongoing corporate developments.
Outlook is balanced with growth potential from product innovation and acquisition synergies, but risks include earnings volatility, high valuation multiples, and shareholder litigation over the merger terms. Institutional sentiment is split evenly between buy and hold ratings, reflecting cautious optimism amid execution challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Nvidia Corp
NVIDIA Corporation designs, develops, and markets three dimensional (3D) graphics processors and related software. The Company offers products that provides interactive 3D graphics to the mainstream personal computer market.
Read more on NVDA →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
